The Intelligence from The Economist cover image

More needles in the haystack: vaccine candidates proliferate

The Intelligence from The Economist

00:00

Evaluating COVID-19 Vaccines: Novavax and Janssen

This chapter explores the development, efficacy, and distribution advantages of Novavax and Janssen COVID-19 vaccines. It highlights their effectiveness against variants, the need for global variant tracking, and logistical challenges in vaccine delivery.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app